[go: up one dir, main page]

PE20142332A1 - Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas - Google Patents

Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Info

Publication number
PE20142332A1
PE20142332A1 PE2014001174A PE2014001174A PE20142332A1 PE 20142332 A1 PE20142332 A1 PE 20142332A1 PE 2014001174 A PE2014001174 A PE 2014001174A PE 2014001174 A PE2014001174 A PE 2014001174A PE 20142332 A1 PE20142332 A1 PE 20142332A1
Authority
PE
Peru
Prior art keywords
formulation
macromolecle
aggregation
reduce
physiological conditions
Prior art date
Application number
PE2014001174A
Other languages
English (en)
Inventor
Brian Lobo
Sabrina Lo
Aditya Wakankar
Yuchang John Wang
Rita L Wong
Pierre Goldbach
Hanns-Christian Mahler
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142332(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of PE20142332A1 publication Critical patent/PE20142332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

REFERIDA A UNA MACROMOLECULA, LA CUAL ES UNA PROTEINA, PARTICULARMENTE, UN ANTICUERPO ANTI-CD20, DONDE EL ANTICUERPO COMPRENDE LA SECUENCIA DE AMINOACIDOS SELECCIONADA DEL GRUPO SEC ID NO:1-15. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA PARA ADMINISTRACION SUBCUTANEA QUE COMPRENDE AL ANTICUERPO Y DE 5% A 20% DE POLIVINILPIRROLIDONA (PVP). DICHA FORMULACION ES UTIL PARA REDUCIR LA INFLAMACION EN EL SITIO DURANTE LA ADMINISTRACION SUBCUTANEA DE UNA MACROMOLECULA
PE2014001174A 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas PE20142332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11543908P 2008-11-17 2008-11-17

Publications (1)

Publication Number Publication Date
PE20142332A1 true PE20142332A1 (es) 2015-01-29

Family

ID=42170394

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014001174A PE20142332A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
PE2011001039A PE20120204A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001039A PE20120204A1 (es) 2008-11-17 2009-11-16 Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas

Country Status (17)

Country Link
US (2) US20110300135A1 (es)
EP (1) EP2358394A4 (es)
JP (2) JP2012509270A (es)
KR (2) KR20110097772A (es)
CN (2) CN102281902B (es)
AR (1) AR074196A1 (es)
AU (1) AU2009313756B2 (es)
BR (1) BRPI0916042A2 (es)
CA (1) CA2742990A1 (es)
CL (1) CL2011001131A1 (es)
IL (1) IL212532A0 (es)
MX (1) MX2011005056A (es)
PE (2) PE20142332A1 (es)
RU (1) RU2011124527A (es)
TW (1) TW201021831A (es)
WO (1) WO2010057109A1 (es)
ZA (1) ZA201102998B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
CA2950577A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
HK1250997A1 (zh) * 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
JP7341061B2 (ja) 2016-11-22 2023-09-08 エレクトロファイ， インコーポレイテッド 治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
AU2019377456A1 (en) 2018-11-07 2021-05-27 Merck Sharp & Dohme Llc Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
WO2020160323A2 (en) 2019-01-31 2020-08-06 Elektrofi, Inc. Particle formation and morphology
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
WO2020264313A1 (en) * 2019-06-28 2020-12-30 Zymo Research Corporation Compositions for the stabilization of cell-free nucleic acids and methods thereof
JP7781743B2 (ja) * 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
CN116370408B (zh) * 2020-06-17 2025-12-02 成都瑞沐生物医药科技有限公司 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂
US12351643B2 (en) 2020-11-04 2025-07-08 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
US12492261B2 (en) 2020-11-04 2025-12-09 Genentech, Inc. Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies
TWI838660B (zh) 2020-11-04 2024-04-11 美商建南德克公司 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
US11958906B2 (en) 2022-04-13 2024-04-16 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1572744B1 (en) * 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
UA99933C2 (ru) * 2003-04-09 2012-10-25 Дженентек, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP2164871A2 (en) * 2007-06-12 2010-03-24 Wyeth a Corporation of the State of Delaware Anti-cd20 therapeutic compositions and methods

Also Published As

Publication number Publication date
ZA201102998B (en) 2013-06-26
BRPI0916042A2 (pt) 2015-11-10
JP2015157820A (ja) 2015-09-03
IL212532A0 (en) 2011-06-30
EP2358394A4 (en) 2013-03-06
JP2012509270A (ja) 2012-04-19
US20110300135A1 (en) 2011-12-08
CN102281902A (zh) 2011-12-14
CA2742990A1 (en) 2010-05-20
PE20120204A1 (es) 2012-03-03
CN102281902B (zh) 2013-11-13
AU2009313756A1 (en) 2010-05-20
AU2009313756B2 (en) 2015-02-26
MX2011005056A (es) 2011-05-31
TW201021831A (en) 2010-06-16
CN103705930A (zh) 2014-04-09
HK1164750A1 (en) 2012-09-28
RU2011124527A (ru) 2012-12-27
KR20140133588A (ko) 2014-11-19
AR074196A1 (es) 2010-12-29
WO2010057109A1 (en) 2010-05-20
KR20110097772A (ko) 2011-08-31
EP2358394A1 (en) 2011-08-24
CL2011001131A1 (es) 2012-02-03
US20140308270A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
PE20142332A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
AR070276A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion.
PE20120169A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EA201001002A1 (ru) Твердые липидные микрокапсулы, содержащие гормон роста во внутреннем твердом ядре
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2013005341A (es) Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
UY35018A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico.
MX347504B (es) Formulaciones concentradas de proteina y usos de las mismas.
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
EP2896632A3 (en) Material and methods for treating or preventing HER-3 associated diseases
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
JP2016539921A5 (es)
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
RU2014102940A (ru) Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов
MX354535B (es) TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.
CU20110042A7 (es) Molécula inmunogénica que comprende un ligando de invasión dirigido a un receptor resistente a proteasas
RU2014102936A (ru) Композиции противораковой вакцины, содержащей пептид wt1, для трансдермального введения
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
PH12014500765A1 (en) Human notch1 decoys
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.

Legal Events

Date Code Title Description
FD Application declared void or lapsed